FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:1692-1698 May 30, 2002 Number 22 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Gale, E. A.M. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Type 1 diabetes mellitus is a chronic autoimmune disease caused by the pathogenic action of T lymphocytes on insulin-producing beta cells. Previous clinical studies have shown that continuous immune suppression temporarily slows the loss of insulin production. Preclinical studies suggested that a monoclonal antibody against CD3 could reverse hyperglycemia at presentation and induce tolerance to recurrent disease.

Methods We studied the effects of a nonactivating humanized monoclonal antibody against CD3 — hOKT31(Ala-Ala) — on the loss of insulin production in patients with type 1 diabetes mellitus. Within 6 weeks after diagnosis, 24 patients were randomly assigned to receive either a single 14-day course of treatment with the monoclonal antibody or no antibody and were studied during the first year of disease.

Results Treatment with the monoclonal antibody maintained or improved insulin production after one year in 9 of the 12 patients in the treatment group, whereas only 2 of the 12 controls had a sustained response (P=0.01). The treatment effect on insulin responses lasted for at least 12 months after diagnosis. Glycosylated hemoglobin levels and insulin doses were also reduced in the monoclonal-antibody group. No severe side effects occurred, and the most common side effects were fever, rash, and anemia. Clinical responses were associated with a change in the ratio of CD4+ T cells to CD8+ T cells 30 and 90 days after treatment.

Conclusions Treatment with hOKT31(Ala-Ala) mitigates the deterioration in insulin production and improves metabolic control during the first year of type 1 diabetes mellitus in the majority of patients. The mechanism of action of the anti-CD3 monoclonal antibody may involve direct effects on pathogenic T cells, the induction of populations of regulatory cells, or both.

Source Information

From the Naomi Berrie Diabetes Center and the Department of Medicine, Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York (K.C.H., E.P.-R., L.T.); Pacific Northwest Research Institute, Seattle (W.H.); the University of Chicago, Chicago (J.A.A.); the University of Utah, Salt Lake City (D.D.); the Departments of Pediatrics (S.E.G.) and Medicine (J.A.B.), University of California at San Francisco, San Francisco; the National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md. (D.M.H.); and the R.W. Johnson Pharmaceutical Research Institute, Raritan, N.J. (D.X., R.A.Z.).

Address reprint requests to Dr. Herold at Columbia University, 1150 St. Nicholas Ave., New York, NY 10032, or at kh318{at}columbia.edu.

Full Text of this Article

Related Letters:

Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus
Killestein J., Herold K. C., Bluestone J. A.
Extract | Full Text | PDF  
N Engl J Med 2002; 347:1116-1117, Oct 3, 2002. Correspondence

This article has been cited by other articles:

• Pietropaolo, M., Surhigh, J. M., Nelson, P. W., Eisenbarth, G. S. (2008). Primer: Immunity and Autoimmunity. Diabetes 57: 2872-2882 [Full Text]  
• Fiorina, P., Vergani, A., Dada, S., Jurewicz, M., Wong, M., Law, K., Wu, E., Tian, Z., Abdi, R., Guleria, I., Rodig, S., Dunussi-Joannopoulos, K., Bluestone, J., Sayegh, M. H. (2008). Targeting CD22 Reprograms B-Cells and Reverses Autoimmune Diabetes. Diabetes 57: 3013-3024 [Abstract] [Full Text]  
• Koulmanda, M., Bhasin, M., Hoffman, L., Fan, Z., Qipo, A., Shi, H., Bonner-Weir, S., Putheti, P., Degauque, N., Libermann, T. A., Auchincloss, H. Jr., Flier, J. S., Strom, T. B. (2008). Curative and {beta} cell regenerative effects of {alpha}1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc. Natl. Acad. Sci. USA 105: 16242-16247 [Abstract] [Full Text]  
• Rigby, M. R., Trexler, A. M., Pearson, T. C., Larsen, C. P. (2008). CD28/CD154 Blockade Prevents Autoimmune Diabetes by Inducing Nondeletional Tolerance After Effector T-Cell Inhibition and Regulatory T-Cell Expansion. Diabetes 57: 2672-2683 [Abstract] [Full Text]  
• Isaacs, J. D. (2008). Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future. Rheumatology (Oxford) 47: 1461-1468 [Abstract] [Full Text]  
• DeVoss, J. J., Shum, A. K., Johannes, K. P. A., Lu, W., Krawisz, A. K., Wang, P., Yang, T., LeClair, N. P., Austin, C., Strauss, E. C., Anderson, M. S. (2008). Effector Mechanisms of the Autoimmune Syndrome in the Murine Model of Autoimmune Polyglandular Syndrome Type 1. J. Immunol. 181: 4072-4079 [Abstract] [Full Text]  
• Donath, M. Y., Storling, J., Berchtold, L. A., Billestrup, N., Mandrup-Poulsen, T. (2008). Cytokines and {beta}-Cell Biology: from Concept to Clinical Translation. Endocr. Rev. 29: 334-350 [Abstract] [Full Text]  
• Roep, B. O. (2008). Islet Autoreactive CD8 T-cells in Type 1 Diabetes: Licensed to Kill?. Diabetes 57: 1156-1156 [Full Text]  
• Martinuzzi, E., Novelli, G., Scotto, M., Blancou, P., Bach, J.-M., Chaillous, L., Bruno, G., Chatenoud, L., van Endert, P., Mallone, R. (2008). The Frequency and Immunodominance of Islet-Specific CD8+ T-cell Responses Change after Type 1 Diabetes Diagnosis and Treatment. Diabetes 57: 1312-1320 [Abstract] [Full Text]  
• Chen, G., Han, G., Wang, J., Wang, R., Xu, R., Shen, B., Qian, J., Li, Y. (2008). Induction of Active Tolerance and Involvement of CD1d-Restricted Natural Killer T Cells in Anti-CD3 F(ab')2 Treatment-Reversed New-Onset Diabetes in Nonobese Diabetic Mice. Am. J. Pathol. 172: 972-979 [Abstract] [Full Text]  
• Simon, G., Parker, M., Ramiya, V., Wasserfall, C., Huang, Y., Bresson, D., Schwartz, R. F., Campbell-Thompson, M., Tenace, L., Brusko, T., Xue, S., Scaria, A., Lukason, M., Eisenbeis, S., Williams, J., Clare-Salzler, M., Schatz, D., Kaplan, B., Von Herrath, M., Womer, K., Atkinson, M. A. (2008). Murine Antithymocyte Globulin Therapy Alters Disease Progression in NOD Mice by a Time-Dependent Induction of Immunoregulation. Diabetes 57: 405-414 [Abstract] [Full Text]  
• Ruzek, M. C., Waire, J. S., Hopkins, D., LaCorcia, G., Sullivan, J., Roberts, B. L., Richards, S. M., Nahill, S. R., Williams, J. M., Scaria, A., Dzuris, J., Shankara, S., Garman, R. D. (2008). Characterization of in vitro antimurine thymocyte globulin-induced regulatory T cells that inhibit graft-versus-host disease in vivo. Blood 111: 1726-1734 [Abstract] [Full Text]  
• Weisberg, S. P., Leibel, R. L. (2008). An Apparent Role for Alox15 in the Pathogenesis of Diabetes in the NOD Mouse: Parsing the Supporting Genetic Data. Diabetes 57: 1-2 [Full Text]  
• Urban, V. S., Kiss, J., Kovacs, J., Gocza, E., Vas, V., Monostori, E., Uher, F. (2008). Mesenchymal Stem Cells Cooperate with Bone Marrow Cells in Therapy of Diabetes. Stem Cells 26: 244-253 [Abstract] [Full Text]  
• Alizadeh, B. Z., Valdigem, G., Coenen, M. J.H., Zhernakova, A., Franke, B., Monsuur, A., van Riel, P. L.C.M., Barrera, P., Radstake, T. R.D.J., Roep, B. O., Wijmenga, C., Koeleman, B. P.C. (2007). Association analysis of functional variants of the FcgRIIa and FcgRIIIa genes with type 1 diabetes, celiac disease and rheumatoid arthritis. Hum Mol Genet 16: 2552-2559 [Abstract] [Full Text]  
• Sherry, N. A., Chen, W., Kushner, J. A., Glandt, M., Tang, Q., Tsai, S., Santamaria, P., Bluestone, J. A., Brillantes, A.-M. B., Herold, K. C. (2007). Exendin-4 Improves Reversal of Diabetes in NOD Mice Treated with Anti-CD3 Monoclonal Antibody by Enhancing Recovery of {beta}-Cells. Endocrinology 148: 5136-5144 [Abstract] [Full Text]  
• Chung, D. T., Korn, T., Richard, J., Ruzek, M., Kohm, A. P., Miller, S., Nahill, S., Oukka, M. (2007). Anti-thymocyte globulin (ATG) prevents autoimmune encephalomyelitis by expanding myelin antigen-specific Foxp3+ regulatory T cells. Int Immunol 0: dxm078v1- [Abstract] [Full Text]  
• Koulmanda, M., Budo, E., Bonner-Weir, S., Qipo, A., Putheti, P., Degauque, N., Shi, H., Fan, Z., Flier, J. S., Auchincloss, H. Jr., Zheng, X. X., Strom, T. B. (2007). Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts. Proc. Natl. Acad. Sci. USA 104: 13074-13079 [Abstract] [Full Text]  
• Voltarelli, J. C., Couri, C. E. B., Stracieri, A. B. P. L., Oliveira, M. C., Moraes, D. A., Pieroni, F., Coutinho, M., Malmegrim, K. C. R., Foss-Freitas, M. C., Simoes, B. P., Foss, M. C., Squiers, E., Burt, R. K. (2007). Ethics of Hematopoietic Stem Cell Transplantation in Type 1 Diabetes Mellitus--Reply. JAMA 298: 285-286 [Full Text]  
• Voltarelli, J. C., Couri, C. E. B., Stracieri, A. B. P. L., Oliveira, M. C., Moraes, D. A., Pieroni, F., Coutinho, M., Malmegrim, K. C. R., Foss-Freitas, M. C., Simoes, B. P., Foss, M. C., Squiers, E., Burt, R. K. (2007). Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus. JAMA 297: 1568-1576 [Abstract] [Full Text]  
• Skyler, J. S. (2007). Cellular Therapy for Type 1 Diabetes: Has the Time Come?. JAMA 297: 1599-1600 [Full Text]  
• You, S., Leforban, B., Garcia, C., Bach, J.-F., Bluestone, J. A., Chatenoud, L. (2007). Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc. Natl. Acad. Sci. USA 104: 6335-6340 [Abstract] [Full Text]  
• Mallone, R., Martinuzzi, E., Blancou, P., Novelli, G., Afonso, G., Dolz, M., Bruno, G., Chaillous, L., Chatenoud, L., Bach, J.-M., van Endert, P. (2007). CD8+ T-Cell Responses Identify {beta}-Cell Autoimmunity in Human Type 1 Diabetes. Diabetes 56: 613-621 [Abstract] [Full Text]  
• Phillips, J. M., O'Reilly, L., Bland, C., Foulis, A. K., Cooke, A. (2007). Patients With Chronic Pancreatitis Have Islet Progenitor Cells in Their Ducts, but Reversal of Overt Diabetes in NOD Mice by Anti-CD3 Shows No Evidence for Islet Regeneration. Diabetes 56: 634-640 [Abstract] [Full Text]  
• Zhang, C., Todorov, I., Lin, C.-L., Atkinson, M., Kandeel, F., Forman, S., Zeng, D. (2007). Elimination of insulitis and augmentation of islet beta cell regeneration via induction of chimerism in overtly diabetic NOD mice. Proc. Natl. Acad. Sci. USA 104: 2337-2342 [Abstract] [Full Text]  
• Tarbell, K. V., Petit, L., Zuo, X., Toy, P., Luo, X., Mqadmi, A., Yang, H., Suthanthiran, M., Mojsov, S., Steinman, R. M. (2007). Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. JEM 204: 191-201 [Abstract] [Full Text]  
• Zhang, C., Lou, J., Li, N., Todorov, I., Lin, C.-L., Cao, Y.-A., Contag, C. H., Kandeel, F., Forman, S., Zeng, D. (2007). Donor CD8+ T Cells Mediate Graft-versus-Leukemia Activity without Clinical Signs of Graft-versus-Host Disease in Recipients Conditioned with Anti-CD3 Monoclonal Antibody. J. Immunol. 178: 838-850 [Abstract] [Full Text]  
• Johnston, S. L (2007). Biologic therapies: what and when?. J. Clin. Pathol. 60: 8-17 [Abstract] [Full Text]  
• Hanninen, A., Nurmela, R., Maksimow, M., Heino, J., Jalkanen, S., Kurts, C. (2007). Islet {beta}-Cell-Specific T Cells Can Use Different Homing Mechanisms to Infiltrate and Destroy Pancreatic Islets. Am. J. Pathol. 170: 240-250 [Abstract] [Full Text]  
• Sherry, N. A., Kushner, J. A., Glandt, M., Kitamura, T., Brillantes, A.-M. B., Herold, K. C. (2006). Effects of Autoimmunity and Immune Therapy on {beta}-Cell Turnover in Type 1 Diabetes. Diabetes 55: 3238-3245 [Abstract] [Full Text]  
• Fife, B. T., Guleria, I., Gubbels Bupp, M., Eagar, T. N., Tang, Q., Bour-Jordan, H., Yagita, H., Azuma, M., Sayegh, M. H., Bluestone, J. A. (2006). Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. JEM 203: 2737-2747 [Abstract] [Full Text]  
• Beeton, C., Wulff, H., Standifer, N. E., Azam, P., Mullen, K. M., Pennington, M. W., Kolski-Andreaco, A., Wei, E., Grino, A., Counts, D. R., Wang, P. H., LeeHealey, C. J., S. Andrews, B., Sankaranarayanan, A., Homerick, D., Roeck, W. W., Tehranzadeh, J., Stanhope, K. L., Zimin, P., Havel, P. J., Griffey, S., Knaus, H.-G., Nepom, G. T., Gutman, G. A., Calabresi, P. A., Chandy, K. G. (2006). Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc. Natl. Acad. Sci. USA 103: 17414-17419 [Abstract] [Full Text]  
• Goronzy, J. J., Weyand, C. M. (2006). Immunosuppression in Atherosclerosis: Mobilizing the Opposition Within. Circulation 114: 1901-1904 [Full Text]  
• Steffens, S., Burger, F., Pelli, G., Dean, Y., Elson, G., Kosco-Vilbois, M., Chatenoud, L., Mach, F. (2006). Short-Term Treatment With Anti-CD3 Antibody Reduces the Development and Progression of Atherosclerosis in Mice. Circulation 114: 1977-1984 [Abstract] [Full Text]  
• Loser, K., Beissert, S. (2006). Therapeutic modulation of cutaneous autoimmunity by regulatory T cells. Rheumatology (Oxford) 45: iii20-iii22 [Abstract] [Full Text]  
• Seyfert-Margolis, V., Gisler, T. D., Asare, A. L., Wang, R. S., Dosch, H. M., Brooks-Worrell, B., Eisenbarth, G. S., Palmer, J. P., Greenbaum, C. J., Gitelman, S. E., Nepom, G. T., Bluestone, J. A., Herold, K. C. (2006). Analysis of T-Cell Assays to Measure Autoimmune Responses in Subjects With Type 1 Diabetes: Results of a Blinded Controlled Study. Diabetes 55: 2588-2594 [Abstract] [Full Text]  
• Liu, W., Putnam, A. L., Xu-yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. A., Kapranov, P., Gingeras, T. R., de St. Groth, B. F., Clayberger, C., Soper, D. M., Ziegler, S. F., Bluestone, J. A. (2006). CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. JEM 203: 1701-1711 [Abstract] [Full Text]  
• Melton, D. A. (2006). Reversal of type 1 diabetes in mice.. NEJM 355: 89-90 [Full Text]  
• Miao, C. H., Ye, P., Thompson, A. R., Rawlings, D. J., Ochs, H. D. (2006). Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice. Blood 108: 19-27 [Abstract] [Full Text]  
• Huurman, V. A.L., Kalpoe, J. S., van de Linde, P., Vaessen, N., Ringers, J., Kroes, A. C.M., Roep, B. O., De Fijter, J. W. (2006). Choice of Antibody Immunotherapy Influences Cytomegalovirus Viremia in Simultaneous Pancreas-Kidney Transplant Recipients. Diabetes Care 29: 842-847 [Abstract] [Full Text]  
• Minamimura, K., Gao, W., Maki, T. (2006). CD4+ Regulatory T Cells Are Spared from Deletion by Antilymphocyte Serum, a Polyclonal Anti-T Cell Antibody. J. Immunol. 176: 4125-4132 [Abstract] [Full Text]  
• Cozar-Castellano, I., Weinstock, M., Haught, M., Velazquez-Garcia, S., Sipula, D., Stewart, A. F. (2006). Evaluation of {beta}-Cell Replication in Mice Transgenic for Hepatocyte Growth Factor and Placental Lactogen: Comprehensive Characterization of the G1/S Regulatory Proteins Reveals Unique Involvement of p21cip. Diabetes 55: 70-77 [Abstract] [Full Text]  
• Shigihara, T., Shimada, A., Oikawa, Y., Yoneyama, H., Kanazawa, Y., Okubo, Y., Matsushima, K., Yamato, E., Miyazaki, J.-i., Kasuga, A., Saruta, T., Narumi, S. (2005). CXCL10 DNA Vaccination Prevents Spontaneous Diabetes through Enhanced {beta} Cell Proliferation in NOD Mice. J. Immunol. 175: 8401-8408 [Abstract] [Full Text]  
• Palmer, J. P., Hampe, C. S., Chiu, H., Goel, A., Brooks-Worrell, B. M. (2005). Is Latent Autoimmune Diabetes in Adults Distinct From Type 1 Diabetes or Just Type 1 Diabetes at an Older Age?. Diabetes 54: S62-S67 [Abstract] [Full Text]  
• Stenstrom, G., Gottsater, A., Bakhtadze, E., Berger, B., Sundkvist, G. (2005). Latent Autoimmune Diabetes in Adults: Definition, Prevalence, {beta}-Cell Function, and Treatment. Diabetes 54: S68-S72 [Abstract] [Full Text]  
• Bottino, R., Trucco, M. (2005). Multifaceted Therapeutic Approaches for a Multigenic Disease. Diabetes 54: S79-S86 [Abstract] [Full Text]  
• Mallone, R., Kochik, S. A., Reijonen, H., Carson, B., Ziegler, S. F., Kwok, W. W., Nepom, G. T. (2005). Functional avidity directs T-cell fate in autoreactive CD4+ T cells. Blood 106: 2798-2805 [Abstract] [Full Text]  
• Narendran, P., Estella, E., Fourlanos, S. (2005). Immunology of type 1 diabetes. QJM 98: 547-556 [Full Text]  
• Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., Schandene, L., Crenier, L., De Block, C., Seigneurin, J.-M., De Pauw, P., Pierard, D., Weets, I., Rebello, P., Bird, P., Berrie, E., Frewin, M., Waldmann, H., Bach, J.-F., Pipeleers, D., Chatenoud, L. (2005). Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes. NEJM 352: 2598-2608 [Abstract] [Full Text]  
• Lernmark, A. (2005). Type 1 Diabetes -- Does Suppressing T Cells Increase Insulin?. NEJM 352: 2642-2644 [Full Text]  
• Herold, K. C., Gitelman, S. E., Masharani, U., Hagopian, W., Bisikirska, B., Donaldson, D., Rother, K., Diamond, B., Harlan, D. M., Bluestone, J. A. (2005). A Single Course of Anti-CD3 Monoclonal Antibody hOKT3{gamma}1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes. Diabetes 54: 1763-1769 [Abstract] [Full Text]  
• Atkinson, M. A. (2005). Thirty Years of Investigating the Autoimmune Basis for Type 1 Diabetes: Why Can't We Prevent or Reverse This Disease?. Diabetes 54: 1253-1263 [Abstract] [Full Text]  
• Kohm, A. P., Williams, J. S., Bickford, A. L., McMahon, J. S., Chatenoud, L., Bach, J.-F., Bluestone, J. A., Miller, S. D. (2005). Treatment with Nonmitogenic Anti-CD3 Monoclonal Antibody Induces CD4+ T Cell Unresponsiveness and Functional Reversal of Established Experimental Autoimmune Encephalomyelitis. J. Immunol. 174: 4525-4534 [Abstract] [Full Text]  
• Liang, Y., Huang, T., Zhang, C., Todorov, I., Atkinson, M., Kandeel, F., Forman, S., Zeng, D. (2005). Donor CD8+ T cells facilitate induction of chimerism and tolerance without GVHD in autoimmune NOD mice conditioned with anti-CD3 mAb. Blood 105: 2180-2188 [Abstract] [Full Text]  
• Jaeckel, E., von Boehmer, H., Manns, M. P. (2005). Antigen-Specific FoxP3-Transduced T-Cells Can Control Established Type 1 Diabetes. Diabetes 54: 306-310 [Abstract] [Full Text]  
• Lindley, S., Dayan, C. M., Bishop, A., Roep, B. O., Peakman, M., Tree, T. I.M. (2005). Defective Suppressor Function in CD4+CD25+ T-Cells From Patients With Type 1 Diabetes. Diabetes 54: 92-99 [Abstract] [Full Text]  
• Huang, M., Matthews, K., Siahaan, T. J., Kevil, C. G. (2005). {alpha}L-Integrin I domain cyclic peptide antagonist selectively inhibits T cell adhesion to pancreatic islet microvascular endothelium. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G67-G73 [Abstract] [Full Text]  
• Halloran, P. F. (2004). Immunosuppressive Drugs for Kidney Transplantation. NEJM 351: 2715-2729 [Full Text]  
• Bluestone, J. A., Tang, Q. (2004). Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells. Proc. Natl. Acad. Sci. USA 101: 14622-14626 [Abstract] [Full Text]  
• Yang, W., Hussain, S., Mi, Q.-S., Santamaria, P., Delovitch, T. L. (2004). Perturbed Homeostasis of Peripheral T Cells Elicits Decreased Susceptibility to Anti-CD3-Induced Apoptosis in Prediabetic Nonobese Diabetic Mice. J. Immunol. 173: 4407-4416 [Abstract] [Full Text]  
• Shi, Q., Wang, D., Hadley, G. A., Bingaman, A. W., Bartlett, S. T., Farber, D. L. (2004). Long-Term Islet Graft Survival in NOD Mice by Abrogation of Recurrent Autoimmunity. Diabetes 53: 2338-2345 [Abstract] [Full Text]  
• Steinman, L. (2004). Immune Therapy for Autoimmune Diseases. Science 305: 212-216 [Abstract] [Full Text]  
• Fradkin, J. (2004). Diabetes Clinical Trials: What Is New at NIDDK?. Clin. Diabetes 22: 109-112 [Full Text]  
• Ogawa, N., List, J. F., Habener, J. F., Maki, T. (2004). Cure of Overt Diabetes in NOD Mice by Transient Treatment With Anti-Lymphocyte Serum and Exendin-4. Diabetes 53: 1700-1705 [Abstract] [Full Text]  
• Herman, A. E., Freeman, G. J., Mathis, D., Benoist, C. (2004). CD4+CD25+ T Regulatory Cells Dependent on ICOS Promote Regulation of Effector Cells in the Prediabetic Lesion. JEM 199: 1479-1489 [Abstract] [Full Text]  
• Schade, A. E., Levine, A. D. (2004). Cutting Edge: Extracellular Signal-Regulated Kinases 1/2 Function as Integrators of TCR Signal Strength. J. Immunol. 172: 5828-5832 [Abstract] [Full Text]  
• Eisenbarth, G. S., Gottlieb, P. A. (2004). Autoimmune Polyendocrine Syndromes. NEJM 350: 2068-2079 [Full Text]  
• Kriegel, M. A., Lohmann, T., Gabler, C., Blank, N., Kalden, J. R., Lorenz, H.-M. (2004). Defective Suppressor Function of Human CD4+ CD25+ Regulatory T Cells in Autoimmune Polyglandular Syndrome Type II. JEM 199: 1285-1291 [Abstract] [Full Text]  
• Mallone, R., Kochik, S. A., Laughlin, E. M., Gersuk, V. H., Reijonen, H., Kwok, W. W., Nepom, G. T. (2004). Differential Recognition and Activation Thresholds in Human Autoreactive GAD-Specific T-Cells. Diabetes 53: 971-977 [Abstract] [Full Text]  
• Devendra, D., Liu, E., Eisenbarth, G. S (2004). Type 1 diabetes: recent developments. BMJ 328: 750-754 [Full Text]  
• Steele, C., Hagopian, W. A., Gitelman, S., Masharani, U., Cavaghan, M., Rother, K. I., Donaldson, D., Harlan, D. M., Bluestone, J., Herold, K. C. (2004). Insulin Secretion in Type 1 Diabetes. Diabetes 53: 426-433 [Abstract] [Full Text]  
• Yu, X.-Z., Levin, S. D., Madrenas, J., Anasetti, C. (2004). Lck Is Required for Activation-Induced T Cell Death after TCR Ligation with Partial Agonists. J. Immunol. 172: 1437-1443 [Abstract] [Full Text]  
• Palmer, J. P., Fleming, G. A., Greenbaum, C. J., Herold, K. C., Jansa, L. D., Kolb, H., Lachin, J. M., Polonsky, K. S., Pozzilli, P., Skyler, J. S., Steffes, M. W. (2004). C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve {beta}-Cell Function: Report of an ADA Workshop, 21-22 October 2001. Diabetes 53: 250-264 [Abstract] [Full Text]  
• Masteller, E. L., Warner, M. R., Ferlin, W., Judkowski, V., Wilson, D., Glaichenhaus, N., Bluestone, J. A. (2003). Peptide-MHC Class II Dimers as Therapeutics to Modulate Antigen-Specific T Cell Responses in Autoimmune Diabetes. J. Immunol. 171: 5587-5595 [Abstract] [Full Text]  
• Bloomgarden, Z. T. (2003). Diabetes Issues in Women and Children: Polycystic ovary syndrome. Diabetes Care 26: 2457-2463 [Full Text]  
• Ansari, M. J. I., Salama, A. D., Chitnis, T., Smith, R. N., Yagita, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., Auchincloss, H. Jr., Sayegh, M. H. (2003). The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice. JEM 198: 63-69 [Abstract] [Full Text]  
• Hathout, E, Lakey, J, Shapiro, J (2003). Islet transplant: an option for childhood diabetes?. Arch. Dis. Child. 88: 591-594 [Abstract] [Full Text]  
• Tang, Q., Smith, J. A., Szot, G. L., Zhou, P., Alegre, M.-L., Henriksen, K. J., Thompson, C. B., Bluestone, J. A. (2003). CD28/B7 Regulation of Anti-CD3-Mediated Immunosuppression In Vivo. J. Immunol. 170: 1510-1516 [Abstract] [Full Text]  
• (2003). Lucina. Arch. Dis. Child. 88: 94-94 [Full Text]  
• Killestein, J., Herold, K. C., Bluestone, J. A. (2002). Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus. NEJM 347: 1116-1117 [Full Text]  
• Ahmadzadeh, M., Farber, D. L. (2002). Functional plasticity of an antigen-specific memory CD4 T cell population. Proc. Natl. Acad. Sci. USA 99: 11802-11807 [Abstract] [Full Text]  
• (2002). New Approaches to Type 1 Diabetes: Some Promises, Some Failures. JWatch Pediatrics 2002: 1-1 [Full Text]  
• (2002). Natural History of Early Diabetes. Journal Watch Dermatology 2002: 7-7 [Full Text]  
• (2002). Natural History of Early Diabetes. JWatch General 2002: 2-2 [Full Text]  
• Gale, E. A.M. (2002). Can We Change the Course of Beta-Cell Destruction in Type 1 Diabetes?. NEJM 346: 1740-1742 [Full Text]